BioWorld

May 3, 2002

AVI Starting Avicine Phase III To Speed Approval Timeline

AVI BioPharma Inc. changed the course for its lead anticancer product, the vaccine Avicine, in an effort to shorten the route toward a possible FDA approval. (BioWorld Today) Read More

Syrrx Enters Deal To Provide Roche With Protein Structures

Demyelination Is Mycobacterium leprae’s Nerve Killer In Infectious And Neurodegenerative Diseases

Nyxis Getting Ready To Move Glyxins Family Into The Clinic

Other News To Note

Quarterly Earnings Reports

Today's news in brief

BioWorld

BioWorld briefs for March 24, 2026.

ADPD 2026: Can we prevent dementia? Scientists quantify it

BioWorld

Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...

Illustration of Alzheimer's disease in the brain

ADPD 2026: Three inflection points to target Alzheimer’s disease

BioWorld Science

A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...

Emerging therapeutic strategies for Parkinson’s at ADPD 2026

BioWorld

Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...

News in brief

BioWorld Asia

BioWorld Asia briefs for March 24, 2026